Min et al. showed CYP7A1 to be downregulated in liver samples of NASH patients compared to healthy controls and reported alterations in cholesterol and bile acid homeostatic pathways to be linked to disease severity [52]. The gene discussed is CYP7A1; the disease is metabolic dysfunction-associated steatohepatitis.